April 10th 2024
Study participants in the treatment group experienced an observable and significant decrease in melanin index scoring.
February 16th 2024
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Vitiligo treatment difficult, not impossible
October 2nd 2019Newer and emerging modalities are addressing the need for better therapeutic options for vitiligo, but there remains a broader need for dermatologists to understand the existing, useful therapies for this disfiguring, but undertreated autoimmune condition.
Consensus agreement outlines terminology to describe pigmentary disorders
April 18th 2019New consensus conclusions are important, because managing acquired macular pigmentation is a new frontier in dermatology. The article defines terminology and notes the primary feature common to macular pigmentation conditions.